Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTB-02
- Development stage
- Preclinical
- Lead developer
- Next Innovative Therapeutics
- Administration
- Oral
01
Overview
PTB-02 (also known as PBTX-02 or NTX-02) is a plant-derived nutraceutical developed by Next Innovative Therapeutics (Nintx) to provide digestive support for individuals with non-celiac gluten sensitivity. Formulated using bioactive compounds sourced from Brazilian biodiversity, PTB-02 is designed to modulate the gut microbiome and target biological pathways associated with gluten-induced gastrointestinal discomfort and malabsorption. The development of PTB-02 has reached a completed status, and Nintx plans to launch the formula through a partner laboratory.
Beyond the preview
Go deeper on PTB-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTB-02.